Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in nonalcoholic fatty liver disease

  title={Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in nonalcoholic fatty liver disease},
  author={Taekyeong Yoo and Sae Kyung Joo and Hyo Jung Kim and Hyun Young Kim and Hyungtai Sim and Jieun Lee and Hee-Hoon Kim and Sunhee Jung and Youngha Lee and Oveis Jamialahmadi and Stefano Romeo and Won-Il Jeong and Geum-Sook Hwang and Keon Wook Kang and Jae Woo Kim and Won Kim and Murim Choi},
Background & Aims Nonalcoholic fatty liver disease (NAFLD) poses an impending clinical burden. Genome-wide association studies have revealed a limited contribution of genomic variants to the disease, requiring alternative but robust approaches to identify disease-associated variants and genes. We carried out a disease-specific expression quantitative trait loci (eQTL) screen to identify novel genetic factors that specifically act on NAFLD progression on the basis of genotype. Methods We… 
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications
The latest developments in the field of NAFLD-genomics can be leveraged for identifying novel disease mechanisms and therapeutic targets that may prevent the morbidity and mortality associated with disease progression.


Update on NAFLD genetics: from new variants to the clinic.
Genetics and epigenetics of NAFLD and NASH: Clinical impact.
Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans
The study suggests that the pathogenic role of PnPLA3148M in NAFLD is independent of the gene transcription in humans, which may be attributed to the high endogenous transcription level of PNPLA3 gene in human livers.
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
The genetics of nonalcoholic fatty liver disease is discussed, including evidence of shared genetic modifiers and possible pleiotropic effects between NAFLD and other liver diseases or metabolic disorders and the translational implications and future challenges are discussed.
Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers
It is demonstrated that NASH is genetically and clinically different from the other NAFLD subgroups, and risk-estimation models forNAFLD and NASH using multiple genetic markers can be used to improve the accuracy of NA FLD diagnosis and to guide treatment decisions for patients.
Loss of hepatic Mboat7 leads to liver fibrosis
Mboat7 deficiency in mice and human points to an inflammation-independent pathway of liver fibrosis that may be mediated by lipid signalling and a potentially targetable treatment option in NAFLD.
Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes
DMGV was identified as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offspring cohort of the Framingham Heart Study participants and provided all metabolite peak data consisting of known and unidentified peaks, genetics, and key metabolic parameters as a publicly available resource for investigations in cardiometabolic diseases.
A mega-analysis of expression quantitative trait loci (eQTL) provides insight into the regulatory architecture of gene expression variation in liver
This study generated a first comprehensive map reflecting the genetic regulatory landscape of gene expression in liver, reinforcing the notion that high density lipoprotein metabolism plays a role in AMD pathogenesis.
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
The diagnosis of definite steatohepatitis or the absence of SH based on evaluation of patterns as well as individual lesions on liver biopsies does not always correlate with threshold values of the semiquantitative NAS.